|
N-Acetylcysteine: Multiple Clinical Applications |
60.00% |
|
National Cancer Institute, National Institute of Health: Developmental Therapeutics Program. NSC 631570: results of the Human Ce |
80.00% |
|
Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. |
60.00% |
|
New biochemical mechanisms of the anticancer effect of Ukrain in the treatment of cancer of the urinary bladder |
60.00% |
|
New techniques in radiation therapy for head and neck cancer: IMRT, CyberKnife, protons, and carbon ions. Improved effectiveness and safety? Impact on survival? |
70.00% |
|
New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. |
70.00% |
|
Newcastle disease virus as an oncolytic agent. |
80.00% |
|
NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell |
90.00% |
|
Novel anti-angiogenic therapies for malignant gliomas. |
50.00% |
|
Novel dammarane-type sapogenins from Panax ginseng berry and their biological activities. |
70.00% |
|
Novel strategies to reverse chemoresistance in colorectal cancer |
70.00% |
|
NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial |
85.00% |
|
Nuts and green tea key to cancer treatment? |
60.00% |
|
Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. |
90.00% |
|
Oireachtas Special Committee on COVID-19 Response |
70.00% |
|
Oleic Acid, deglycosylated vitamin D-binding protein, nitric oxide: a molecular triad made lethal to cancer. |
100.00% |
|
Oncologic benefit of tonsillectomy in stage I and II tonsil cancer: a surveillance epidemiology and end results database review |
70.00% |
|
Oncolytic virus therapy for malignant brain tumors |
60.00% |
|
Oncolytic virus therapy for prostate cancer. |
70.00% |
|
Oncolytic Virus Treatment |
70.00% |
|
Open Source Cancer Resaearch - A video |
90.00% |
|
Opioid growth factor and the treatment of human pancreatic cancer: a review. |
90.00% |
|
Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell c |
80.00% |
|
Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. |
55.00% |
|
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytot..... |
80.00% |
|
Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. |
60.00% |
|
Oral metronomic chemotherapy using cyclophosphamide in metastatic patients (pts) after standard treatment: Results of a randomiz |
25.00% |
|
Oral metronomic cyclophosphamide in elderly with metastatic melanoma. |
70.00% |
|
Outpatient administration of high-dose methotrexate for osteosarcoma treatment in Brazil. |
30.00% |
|
Outside the box--novel therapeutic strategies for glioblastoma. |
80.00% |
|
Pancreatic cancer stem cells - insights and perspectives. |
40.00% |
|
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities |
50.00% |
|
Pectin: A Bioactive Food Polysaccharide with Cancer Preventive Potential |
70.00% |
|
Pharmacology and safety factors affecting use of flat (rather than weight-based) dosing of tesetaxel, an orally administered.... |
30.00% |
|
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the |
30.00% |
|
Phase I adjuvant trial of multi-epitope p53 vaccine for patients with squamous cell carcinoma of the head and neck (SCCHN): A pr |
45.00% |
|
Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. |
70.00% |
|
Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors. |
70.00% |
|
Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer. |
80.00% |
|
Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) ...... |
95.00% |
|
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. |
40.00% |
|
Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer |
80.00% |
|
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer |
70.00% |
|
Phase II trial of pharmacodynamically (PDally)-guided optimal biologic dose titration (OBDT) of sorafenib (S) in combination wit |
70.00% |
|
Photodynamic Therapy |
70.00% |
|
Pilot study of a specific dietary supplement in tumor-bearing mice and in stage IIIB and IV non-small cell lung cancer patients. |
80.00% |
|
Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. |
70.00% |
|
Pilot Study of Sentinel-Node-Based Adoptive Immunotherapy in Advanced Colorectal Cancer. |
90.00% |
|
Possible association between nanobacteria and malignant microcalcifications in breast cancer. |
80.00% |
|
Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. |
50.00% |
|
Potential therapeutic efficacy of Ukrain (NSC 631570) in AIDS patients with Kaposi's sarcoma |
80.00% |
|
PPAR gamma agonists can be expected to potentiate the efficacy of metronomic chemotherapy through CD36 up-regulation. |
70.00% |
|
Pre-Clinical Investigations on Ukrain |
90.00% |
|
Preclinical antitumor and antiangiogenic activity of a metronomic schedule of cisplatin against human transitional cell carcinom |
50.00% |
|
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer. |
50.00% |
|
Preliminary pharmacokinetic studies of Ukrain in rats |
|
|
Preliminary studies on the effect of Ukrain on the immunological response in patients with malignant tumours. |
60.00% |
|
Presence of nanobacteria in psammoma bodies of ovarian cancer: evidence for pathogenetic role in intratumoral biomineralization. |
80.00% |
|
Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway. |
80.00% |
|
Prof. Meyl detected DNA-Wave and Scalar Wave Biology |
100.00% |
|
Prof. Meyl upptäckte DNA-vågor och Skalär Våg Biologi |
100.00% |
|
Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment. |
|
|
Programmed drug delivery: nanosystems for tumor targeting. |
60.00% |
|
Propolis Extract (Bio 30) Suppresses the Growth of Human Neurofibromatosis (NF) Tumor Xenografts in Mice |
55.00% |
|
Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador) |
80.00% |
|
Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador). |
90.00% |
|
Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age. |
|
|
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. |
70.00% |
|
Proton Therapy |
70.00% |
|
PSMA - Lutetium Treatment |
|
|
Psorinum therapy in treating stomach, gall bladder, pancreatic, and liver cancers: a prospective clinical study. |
100.00% |
|
Psorinum, the anti cancer miracle from India. |
91.47% |
|
Psychodynamic pain management for cancer patients |
100.00% |
|
Psychodynamic psychotherapy, therapeutic touch and cancer. A review of the method of intervention and studv of 75 cases |
100.00% |
|
Pycnogenol may alleviate adverse effects in oncologic treatment. |
60.00% |
|
Quality of radiosurgery for single brain metastases with respect to treatment technology: a matched-pair analysis. |
70.00% |
|
Radiofrequency ablation |
70.00% |
|
Radiomodification effects of Ukrain, a cytostatic and immunomodulating drug, on intracellular glucocorticoid reception during sh |
60.00% |
|
Radiosurgery for spinal malignant tumors. |
70.00% |
|
Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus u |
50.00% |
|
Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer. |
70.00% |
|
Randomized phase II trial of capecitabine versus capecitabine, low molecular weight heparin, and prednisone in refractory....... |
70.00% |
|
Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119 |
70.00% |
|
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. |
40.00% |
|
Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative.. |
80.00% |
|
Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative.... |
|
|
RECURRENCE OF BRAIN TUMORS MAY BE PREVENTED WITH RUTA AND CALCAREA PHOSPHORICA |
90.00% |
|
Reducing malignant ascites accumulation by repeated intraperitoneal administrations of a Viscum album extract. |
95.00% |
|
Regional hyperthermia in high-risk soft tissue sarcomas. |
80.00% |
|
Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory |
80.00% |
|
Removed because of suspicion of scientific fraud: Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. |
10.00% |
|
Removed from Pubmed because of suspicion of scientific fraud: Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). |
55.00% |
|
Removed from Pubmed because of suspiion of scientific fraud: Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF. |
75.00% |
|
Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status |
60.00% |
|
Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced |
90.00% |
|
Response of brain metastases from breast cancer to megestrol acetate: a case report. |
80.00% |
|
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer |
60.00% |
|
Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer. |
40.00% |
|
Results of Ukrain monotherapy of prostate cancer |
50.00% |
|
Resveratrol |
80.00% |
